Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall Bateman

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Biological Psychiatry|April 2, 2020
Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's DiseaseAlexa Pichet Binette, Étienne Vachon-Presseau, John Morris, et al.
Current Alzheimer Research|August 8, 2013
Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriersShaun M Frost, Yogesan Kanagasingam, Hamid R Sohrabi, et al.
Molecular Neurodegeneration|April 27, 2012
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjectsSaori Hata, Miyako Taniguchi, Yi Piao, et al.
Alzheimer'S Research & Therapy|December 14, 2019
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysisGregory Klein, Paul Delmar, Nicola Voyle, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
Alzheimer'S Research & Therapy|July 5, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 27, 2006
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolismKe-Jie Yin, John R Cirrito, Ping Yan, et al.
Neurobiology of Aging|October 16, 2021
Regional age-related atrophy after screening for preclinical alzheimer diseaseLauren N Koenig, Pamela LaMontagne, Matthew F Glasser, et al.
Annals of Neurology|August 29, 2014
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conferenceBeth-Anne Sieber, Story Landis, Walter Koroshetz, et al.
Research Square|January 23, 2024
Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individualsChengjie Xiong, Suzanne Schindler, Jingqin Luo, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Biological Psychiatry|April 2, 2020
Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's DiseaseAlexa Pichet Binette, Étienne Vachon-Presseau, John Morris, et al.
Current Alzheimer Research|August 8, 2013
Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriersShaun M Frost, Yogesan Kanagasingam, Hamid R Sohrabi, et al.
Molecular Neurodegeneration|April 27, 2012
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjectsSaori Hata, Miyako Taniguchi, Yi Piao, et al.
Alzheimer'S Research & Therapy|December 14, 2019
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysisGregory Klein, Paul Delmar, Nicola Voyle, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
Alzheimer'S Research & Therapy|July 5, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 27, 2006
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolismKe-Jie Yin, John R Cirrito, Ping Yan, et al.
Neurobiology of Aging|October 16, 2021
Regional age-related atrophy after screening for preclinical alzheimer diseaseLauren N Koenig, Pamela LaMontagne, Matthew F Glasser, et al.
Annals of Neurology|August 29, 2014
Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conferenceBeth-Anne Sieber, Story Landis, Walter Koroshetz, et al.
Research Square|January 23, 2024
Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individualsChengjie Xiong, Suzanne Schindler, Jingqin Luo, et al.
Pageof 4